

ASX ANNOUNCEMENT

CEO Presentation

30 May 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to provide the enclosed presentation in respect of the Company's operations, sales, funding, and strategy.

The presentation shall be presented by CEO and Managing Director, Jenni Pilcher, at the Company's Extraordinary General Meeting (**EGM**) of shareholders to be held today at 9:30am.

Authorised for release by the Board of Directors of Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouplimited.com | www.satipharm.com

EXTRAORDINARY GENERAL MEETING

30 MAY 2025



Disclaimer: Important notice

This presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann).

Summary information

This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentation. The information provided in this Presentation pertaining to Cann and its business assets, strategy and operations is for general informational purposes only.

Future performance

This Presentation contains certain 'forward looking statements', including but not limited to projections, guidance on future revenues and other potential synergies and estimates about the future performance of Cann. Forward looking statements can generally be identified by the use of forward-looking words such as, 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target' 'outlook', 'guidance', 'potential' and other similar expressions within the meaning of securities laws of applicable jurisdictions.

The forward-looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Cann, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Cann). There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to Cann as at the date of this Presentation.

Except as required by law or regulation (including the ASX Listing Rules), Cann undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Past performance

Investors should note that past performance, including any historical information in this Presentation cannot be relied upon as an indicator of (and provides no guidance as to) future Cann performance including future share price performance.

All rights reserved

Copyright in this Presentation (including in any photographs) is the property of or is licensed to Cann and is protected under copyright laws. No part of this Presentation may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the Company, except in the case of brief quotations embodied in critical reviews and certain other non-commercial uses permitted by copyright law.







OPERATIONAL HIGHLIGHTS



- April & May medicinal cannabis dried flower production
 > 700 KGs/month → 8.8 Mt annual run rate
- On track to exceed FY2025 target of 5.5 Mt
- Cost per gram produced improving significantly with scale
- Operating costs down 38% YoY, now < \$12M annually



SALES & DISTRIBUTION



- Chemist Warehouse expansion: 11 → 13 outlets
 Purchase orders have commenced
- New distributor discussions in advanced stages



FUNDING & GRANTS



- Received \$836K from Radium Capital
 Advance on FY2025 R&D Tax Credit Refund
- Closed \$1.5M in financing from convertible note facility and equity raise from sophisticated investors
- Restructured debt maturity dates and secured capitalisation of interest payments



STRATEGIC FOCUS



Now firmly focused on strengthening Cann's balance sheet, to position it for future success.

EXTRAORDINARY GENERAL MEETING

30 MAY 2025

Enquiries | contact@canngrouplimited.com

